Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible

MLA

J. R. Infante, et al. “Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Metastatic Urothelial Carcinoma Progressed after Platinum-Based Therapy or Platinum Ineligible.” Annals of Oncology, vol. 27, Oct. 2016, p. vi267. EBSCOhost, https://doi.org/10.1093/annonc/mdw373.05.

APA

J. R. Infante, M. Agrawal, Andrea B. Apolo, K.-W. Lee, Kevin M. Chin, Michael S. Gordon, Manish R. Patel, John Allan Ellerton, Michael Schlichting, & Luc Dirix. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible. Annals of Oncology, 27, vi267. https://doi.org/10.1093/annonc/mdw373.05

Chicago

J. R. Infante, M. Agrawal, Andrea B. Apolo, K.-W. Lee, Kevin M. Chin, Michael S. Gordon, Manish R. Patel, John Allan Ellerton, Michael Schlichting, and Luc Dirix. 2016. “Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Metastatic Urothelial Carcinoma Progressed after Platinum-Based Therapy or Platinum Ineligible.” Annals of Oncology 27 (October): vi267. doi:10.1093/annonc/mdw373.05.